May 14, 2019 / 06:20PM GMT
Juan Esteban Avendano - BofA Merrill Lynch, Research Division - Associate
We'll go ahead and get started. Good morning. Welcome to the 2019 Bank of America Health Care Conference. Once again, my name is Juan Avendano, and I am an analyst in the life sciences tools and diagnostics team, which is led by Derik De Bruin. I focus on coverage of CROs and CDMOs, and I'm pleased to be joined on stage by Charles River. With us, we have David Smith, their CFO; and Birgit Girshick, who runs the Discovery and Safety Assessment segment as well as the Biologics Testing Solutions business. Welcome, and thank you once again for participating.
Questions and Answers:
Juan Esteban Avendano - BofA Merrill Lynch, Research Division - AssociateI guess, David, if you could start us off by summarizing the first quarter results that you just reported last week, that would be great. Thank you.
David Ross Smith - Charles River Laboratories International, Inc. - Corporate Executive VP & CFO
Okay. So in Q1, well, we're pleased with Q1,